Cite
Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study
MLA
Rob Knight, et al. “Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MM): Final Results of a Multicenter Phase I/II Study.” Journal of Clinical Oncology, vol. 28, May 2010, p. 8016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........e770dbee0d0372e5a2f3cf8e3334f0ae&authtype=sso&custid=ns315887.
APA
Rob Knight, KC Anderson, Dixie-Lee Esseltine, Sundar Jagannath, P. G. Richardson, Andrzej Jakubowiak, Noopur Raje, David Avigan, S. Lonial, & Edie Weller. (2010). Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study. Journal of Clinical Oncology, 28, 8016.
Chicago
Rob Knight, KC Anderson, Dixie-Lee Esseltine, Sundar Jagannath, P. G. Richardson, Andrzej Jakubowiak, Noopur Raje, David Avigan, S. Lonial, and Edie Weller. 2010. “Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MM): Final Results of a Multicenter Phase I/II Study.” Journal of Clinical Oncology 28 (May): 8016. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........e770dbee0d0372e5a2f3cf8e3334f0ae&authtype=sso&custid=ns315887.